Source: Eye Future; Editor: SophiaReprint Requirements: Can be reprinted 24 hours after the first publication, source must be credited.
Global Ophthalmology Conference Registration
Recently,Peking Union Medical College HospitalPublish the announcement, in150,000 yuanAnd Sales CommissionFirst five years 5%、3% in the next five yearsThe proposed transaction price will "A kind of usePosterior Scleral Compression Device for High Myopia Patients”Scientific and technological achievements,Transferred toGuangzhou Vesber Biotechnology Co., Ltd.. The transaction has passed the public notice period.
Professor Dai said: "This device is mainlyTreatment of Pathological MyopiaBecause the axial length in pathological myopia is relatively long,Hope to stabilize or shorten the eye axis through this device.. This device is an extension of posterior scleral compression surgery, as allogeneic sclera was primarily used in the past, threaded behind the eyeball and then sutured on both sides to perform the procedure. This surgical operation is relatively complex, with significant trauma and a higher incidence of complications.It may even cause damage to the optic nerve.# Both Parties to the TransactionAchievement Completer: Rongping DaiMale, Deputy Director of the Department of Ophthalmology, Peking Union Medical College Hospital; Chief Physician, Professor, Master's Graduate Supervisor, Doctor of Ophthalmology; specializes in fundus diseases, particularly in the diagnosis and treatment of diabetic retinopathy and age-related macular degeneration; has published over 50 papers and was awarded the Second Prize of Beijing Science and Technology Progress Award.
Recipient: Guangzhou VesberVesber Biotechnology Co., Ltd.VesberVesberFounded in 2007, it is a company focused onOphthalmic Innovation Product R&D, Production, and SalesA national high-tech enterprise located in the core area of the Guangdong-Hong Kong-Macao Greater Bay Area — Nansha District, Guangdong Medical Valley Industrial Park.CompanyRelying on the powerful R&D platform of Zhongshan Ophthalmic Center, the meticulous development of innovative ophthalmic products, with main products includingFoldable Capsular Vitreous Body (FCVB), Foldable Capsular Buckle (FCB), High Myopia Scleral Reinforcement System (HM)etc.FCVB is the world's first artificial organ to save the eyeball, which can precisely simulate the structure and function of the human vitreous body. Since its market launch in 2017,FCVB implantation surgery has been carried out by more than 200 ophthalmologists across over 20 provinces in China, involving more than 150 hospitals, serving more than 3,000 patients.HM is used to delay the progression of myopia and treat conditions such as posterior scleral staphyloma and retinoschisis caused by high myopia. It has currently received ethical review approval from Beijing Tongren Hospital and is undergoing clinical trials in multiple hospitals.# Research and Development BackgroundFundus Lesions in Patients with High Myopia (Over 600 Degrees)Are the three most common in ChinaIrreversible blinding eye diseasesOne of them, where some patients are mainly due toDevelopment of Pathological MyopiaCausing severe fundus complications such as macular schisis, macular hole, macular CNV (choroidal neovascularization), retinal hole, retinal detachment, and posterior scleral staphyloma, with the condition continuously progressing until blindness.In relevant studies both in China and abroad, it has been confirmedScleral Reinforcement Surgery (Including Banding) Can Effectively Halt Further Axial Growth and Reduce Ocular Complications, butThere are still certain limitations, especially in the research of related materials and the refinement of surgical methods.。The main difference between posterior scleral reinforcement surgery and other myopia surgeries lies in——The former belongs toProtective Treatment, which has very important clinical value in delaying the development of myopia and reducing complications in the fundus of the eye.. Especially at this stage, when etiological treatment for pathological myopia is not yet feasible, adopting protective technologies to delay the natural course of pathological myopia can significantly improve patients' quality of life; the latter belongs to refractive surgery, which essentially does not reduce the risk of myopia.DiseasePatients with rational myopia are not advised to undergo refractive surgery to remove glasses.。# Posterior Scleral Buckling DeviceThe invention discloses aPosterior Scleral Compression Device for High Myopia Patients, including a handheld mechanism, with a balloon mechanism installed inside the handheld mechanism, one end of the balloon mechanism extending outside the handheld mechanism, and a pressing mechanism arranged outside the balloon mechanism located outside the handheld mechanism,When using this invention, the first support block is lifted by the first pressurized airbag, and the first support block drives the second support block through the support rod.Apply pressure to the silicone block during lifting., when resetting is required later, since the spring is fixedly connected inside the mounting hole and cannot move, it then enables the spring to pull the second support block downward and elastically press the first support block downward, causingThe first support block and the second support block both return to their original positions and release the lifting of the silicone block., at this timeThe silicone block returns to its original shape under its own elasticity, avoiding any impact on the removal of the entire device.。
In the figure: 1. Handheld mechanism; 11. Handheld end; 12. Pressurizing end; 13. Rubber sleeve; 2. Airbag mechanism; 21. Pressurizing chamber;22, First compression airbag; 23, Through hole; 24, Connecting tube; 25, Second compression airbag; 3, Pressing mechanism; 31, Protective sleeve; 32, Fixing hole; 33, Fixing block; 34, Fixing plate; 4, Compression mechanism; 41, First support block; 42, Support rod; 43, Compression hole; 44, Silicone block; 45, Second support block; 5, Reset mechanism; 51, Mounting plate; 52, Mounting hole; 53, Spring; 6, Positioning mechanism; 61, Positioning rod; 62, Positioning holeThis posterior scleral compression device is designed toThroughPhysical CompressionChange the mechanical state of the posterior sclera of the eyeball, toControl the further growth of the eye axis, thereby reducing the risk of complications in patients with high myopia.。The treatment of posterior scleral staphyloma, macular hole, macular schisis, etc., requires the use of posterior scleral compression. Therefore, the posterior scleral compression device isTreatment of Complications in the Fundus of High MyopiaAn important instrument has been provided.- Both the pressurizing device and the supporting device adoptMade by integrally casting high molecular polymer materials, the pressurization device is elastic, and the materials used conform to medical standards andLow cost, simple manufacturing。
- The clasp and the raised beam form an interference fit, creating a snap connection.Providing a stable fixation structure,Ensure the stability of the device, as well as during the rebound of the pressurization device.Maintain Stability。
- The buckle ring passes under the arched block.The snap ring is elastic., The arch block under the snap ring will support the compression device, causing deformation of the compression device, allowing the compression device to return to its unsupported state after surgery.Provide Power Support。
- The attachment structure isReticular Structure, which can be attached to the eyeball position, reticulated structureMore tightly attached。
- Since the pressurization device itself is elastic, when the buckle ring is removed from the arch block,The compression device will automatically retract, and the elasticity meets the usage requirements.，Easy to operate。
When using this device, the medical staff first places the airbag mechanism behind the patient's ocular sclera through the handheld mechanism.Apply appropriate pressure to the posterior sclera of the eyeball through inflation and deflation operations., prompting the sclera to undergo deformation, thereby altering the mechanical state of the eyeball, achievingControl Axial GrowthThe purpose.In this process, the pressing mechanism ensures the accuracy and stability of the pressure.The device also has a reset function., which can automatically or manually return to its original position after pressurization is completed, avoiding unnecessary damage to the patient.# Initiate Clinical TrialsIt is reported that Vesber has alsoSelf-developedA Highly Myopic Scleral Reinforcement System (HM), used to delay the progression of myopia, and treat posterior scleral staphyloma, retinoschisis, etc., caused by high myopia,Currently undergoing clinical trials at multiple hospitals across China. To date, multiple subjects have been enrolled, with significant clinical outcomes.February 2024,Guangzhou Vesber Biotechnology Co., Ltd.Launched a project with Shanghai Tongren Hospital “Multicenter Clinical Trial of Posterior Scleral Reinforcement System for High Myopia", aiming to demonstrate the operability, safety, and effectiveness of the highly myopic posterior scleral reinforcement system surgery through clinical research.
Currently, several hospitals are conducting this clinical trial.The total number of subjects planned for recruitment in this project is 160., with the purpose of verifying aSafety and Efficacy of a Novel "Highly Myopic Posterior Scleral Reinforcement System" for Treating High Myopia with Macular Schisis; The test product has passed the registration inspection by the Medical Device Quality Supervision and Inspection Center affiliated with the National Medical Products Administration, and meets the conditions for clinical trials.And has successfully conducted exploratory clinical trials on 5 subjects; The hospital ethics committee has approved the implementation of this clinical trial after review.Now,Beijing Tongren Hospital, Renmin Hospital of Wuhan University, Shenzhen Eye HospitalThe kick-off meeting for the "Multicenter Clinical Trial of the Posterior Scleral Reinforcement System for High Myopia" was successfully held, and other multicenter clinical units will also gradually launch the project. Each unit will conduct clinical research.To demonstrate the operability, safety, and effectiveness of the posterior scleral reinforcement system surgery for high myopia., which will benefit a large number of patients with high myopia and macular schisis.# Global Leading Ophthalmic Device and Consumables CompanyCarl Zeiss AG｜Alcon| J&J Vision | Bausch + LombBaushe & Lomb | EssilorEssilor | TopconTopcon | Nidek | CooperC Groupompanies
# Chinese Ophthalmic Devices and Consumables Companies
# Chinese Ophthalmic Medical Service Company
# Overseas Ophthalmology Startups
AEYE Health | Samsara Vision | AcuSurgical | Balance Ophthalmics | CorneaGen | ThermOcular AI
